RAPT Therapeutics Inc (NAS:RAPT)
$ 1.69 -0.12 (-6.63%) Market Cap: 63.27 Mil Enterprise Value: -32.31 Mil PE Ratio: 0 PB Ratio: 0.66 GF Score: 41/100

RAPT Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 05:00PM GMT
Release Date Price: $24.34 (-1.93%)
Anupam Rama JPMorgan;Analyst

All right. Let's go ahead and get started. Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, Malcolm Kuno, and LaRhea Hall. Our next presenting company is RAPT, and presenting on behalf of the company, we have CEO, Brian Wong. Brian?

Brian Wong RAPT Therapeutics
Inc. - President & CEO

Thanks for the introduction, Anupam, and Happy New Year, everyone. Thanks for your interest in RAPT Therapeutics. Actually, joining me from the company today is Rodney Young, our Chief Financial Officer; and Sylvia Wheeler, who leads our IR efforts here as well.

So just to provide some context on the company, RAPT is focused on the discovery, development, and commercialization of oral, small-molecule drugs. The target, the fundamental drivers of inflammation and cancer. We have an in-house proprietary discovery engine that has enabled the rapid progression of a diversified and clinically de

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot